Inclusion Criteria:

          -  Patients with histologically confirmed urothelial cancer.

          -  ECOG Performance status score of 0 or 1.

          -  Cohort 1: Have had progression or recurrence of urothelial cancer following receipt of
             platinum-containing regimen (cisplatin or carboplatin):

               1. Received a first-line platinum-containing regimen in the metastatic setting or
                  for inoperable locally advanced disease;

               2. Or received adjuvant platinum-containing therapy following cystectomy for
                  localized muscle-invasive urothelial cancer, with recurrence/progression ≤12
                  months following completion of therapy.

          -  Cohort 1: In addition to above criterion, must have had progression or recurrence of
             urothelial cancer following receipt of an anti-PD-1 /PD-L1 therapy.

          -  Cohort 2: Were ineligible for cisplatin-based therapy for first line metastatic
             disease and have had progression or recurrence of urothelial cancer after a first-line
             therapy for metastatic disease after an anti-PD-1/PD-L1 therapy.

          -  Adequate hematology, chemistry renal and hepatic function and coagulation values
             without ongoing transfusional.

          -  Subjects must have a 3-month life expectancy.

          -  Have measurable disease by CT or MRI as per RECIST 1.1 criteria.

        Exclusion Criteria:

          -  Women who are pregnant or lactating.

          -  Is currently participating in or has participated in a study of an investigational
             agent or using an investigational device within 4 weeks prior to the first dose of
             trial treatment.

          -  Has a diagnosis of immunodeficiency.

          -  Has had prior irinotecan therapy.

          -  Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study
             Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events
             due to agents administered more than 4 weeks earlier.

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
             baseline) from adverse events due to a previously administered agent.

          -  Requires concomitant medication interfering with ABCA1 transporter or UGT1A1

          -  Subjects with Gilbert's disease.

          -  Has a known additional malignancy that is progressing or requires active treatment.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Has active cardiac disease, Myocardial infarction or unstable angina pectoris within 6
             months of the first date of study therapy.

          -  Has active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease)
             and subjects with a history of bowel obstruction.

          -  Has prior history of clinically significant bleeding, intestinal obstruction, or GI
             perforation within 6 months of enrollment.

          -  Must be at least 2 weeks beyond high dose systemic corticosteroids (however, low dose
             corticosteroids ≤ 20 mg prednisone or equivalent daily are permitted provided the dose
             is stable for 4 weeks).

          -  Has an active infection requiring systemic therapy.

          -  Has a known history of Human Immunodeficiency Virus, Hepatitis B or Hepatitis C

          -  Has other concurrent medical or psychiatric conditions